REBEKAH POINTEK: Open Payments
NPI 1144299694 · WEST HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 75 payments from 24 companies in 2025. Trend: 2023 $1,890 · 2024 $1,970 · 2025 $1,514
Food & beverage: $1,514
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 15 | $189 |
| Novo Nordisk Inc | 8 | $150 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $138 |
| Abbott Laboratories | 5 | $103 |
| Vanda Pharmaceuticals Inc. | 4 | $91 |
| GENZYME CORPORATION | 2 | $72 |
| AstraZeneca Pharmaceuticals LP | 4 | $68 |
| PFIZER INC. | 3 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $57 |
Products named: REZDIFFRA, FREESTYLE LIBRE 3, HETLIOZ, NUCALA, TRELEGY ELLIPTA, DUPIXENT, CUVITRU, UNITHROID.
Industry payments across CT — which companies pay providers there.
